Key facts
- This page summarizes Kyle Guse's Form 4 filing for ATOSSA THERAPEUTICS, INC. (ATOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Mar 2023, 15:10.
Kyle Guse - 02 Mar 2023 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)
- Reporting relationship
- CFO, Gen Counsel and Secretary
- Issuer ticker
- ATOS
- Reported as of
- 02 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 15:10:36 UTC
- Prior SEC filing
- 28 Feb 2022
- Next SEC filing
- 15 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kyle Guse
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kyle Guse filed Form 4 for ATOSSA THERAPEUTICS, INC. (ATOS) on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 28 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATOS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +557,900
- Change %
- Price
- $0.000000
- Shares after
- 557,900
- Date
- 02 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 557,900
- Exercise price
- $0.7200
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date.